IQV Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $4.151 billion, up 8.4% year-over-year (6% at constant currency).
Commercial Solutions Revenue: $1.754 billion, up 11.6% (8.5% at constant currency).
R&D Solutions Revenue: $2.397 billion, up 6.2% (4.2% at constant currency).
Adjusted EBITDA: $932 million, a 5.5% increase year-over-year.
GAAP Net Income: $274 million; GAAP diluted EPS: $1.61.
Adjusted Net Income: $492 million; Adjusted diluted EPS: $2.90, up 7.4% year-over-year.
Cash Flow from Operations: $618 million; Free cash flow: $491 million, a 15% increase year-over-year.
Net Debt: $13.886 billion; Net leverage ratio: 3.62 times trailing twelve-month adjusted EBITDA.

2. Strategic Updates and Business Highlights

AI Integration: Continued deployment of AI solutions, with 192 agents covering 64 use cases. Strong demand from clients for AI-driven analytics and operational improvements.
Commercial Solutions Growth: Notable strength in Patient Solutions and Analytics and Consulting, with a doubling of organic revenue growth in Commercial Solutions and tripling in R&D Solutions.
Record Backlog: Backlog reached $34.2 billion, with $8.9 billion expected to convert to revenue in the next 12 months, reflecting nearly 8% growth year-over-year.
Partnerships: Secured significant contracts with major pharmaceutical companies, including Pfizer and Boehringer Ingelheim, to enhance commercial operations and analytics capabilities.

3. Forward Guidance and Outlook

Full Year 2026 Guidance: Revenue expected between $17.15 billion and $17.35 billion (5.2% to 6.4% growth). Adjusted EBITDA guidance remains between $4.05 billion and $4.25 billion (4.9% to 6.3% growth).
Adjusted Diluted EPS: Raised to a range of $12.65 to $12.95, reflecting 6.1% to 8.6% growth.
Q2 2026 Expectations: Revenue projected between $4.28 billion and $4.34 billion (6.5% to 8% growth), with adjusted EBITDA expected between $955 million and $975 million.

4. Bad News, Challenges, or Points of Concern

Pass-Through Bookings: Unusually low pass-through bookings impacted the book-to-bill ratio, which stood at 1.04. This was attributed to a higher mix of full-service trials, which typically have lower pass-throughs.
Margin Concerns: A 60 basis points contraction in EBITDA margin was noted, primarily due to non-operational headwinds like foreign exchange and pass-throughs. The company emphasized that operationally, margins remained strong.
Market Dynamics: While demand indicators are improving, the company noted that large pharma clients are still taking a cautious approach to capital deployment.

5. Notable Q&A Insights

Bookings and Profitability: Management clarified that the low pass-throughs do not impact profitability, as pass-throughs have zero profitability drop-through. They emphasized that the mix of trials won this quarter was atypical.
Market Stability: There is a cautious optimism regarding the market's recovery, with indications of increased funding and a potential rise in the number of clinical trials driven by AI.
Client Dynamics: Management observed no significant changes in client behavior but noted a stabilization in decision-making speed among large sponsors.
Future Margins: Management indicated that while Q1 margins were impacted by external factors, they expect operational improvements to drive margins positively in the latter half of the year.

Overall, IQVIA demonstrated strong financial performance in Q1 2026, driven by robust growth in both Commercial and R&D Solutions, while navigating challenges related to pass-through bookings and margin pressures. The outlook remains positive, with a focus on AI integration and strategic partnerships.

IQV — IQVIA Holdings Inc.